Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Entera Bio ( (ENTX) ) just unveiled an announcement.
Entera Bio Ltd., a leader in oral peptide development, reported Q3 2024 financial results and business updates, highlighting advancements in their oral PTH(1-34) tablet, EB613, for osteoporosis. The company is anticipating a pivotal FDA ruling on osteoporosis drugs, which could enhance their treatment’s standing. Entera is also progressing with other oral therapies, like GLP-1/glucagon for obesity and GLP-2 for short bowel syndrome, using their proprietary N-Tab™ platform. Financially, Entera reported a net loss of $3 million with sufficient cash to fund operations into Q3 2025.
See more insights into ENTX stock on TipRanks’ Stock Analysis page.